The Cardioprotective Effects of Irbesartan and Candesartan in Isoproterenol Induced Cardiomyopathy in Rats

Jan J. Alshmani

Authors

Jan J. Alshmani

Keywords:

angiotensin, isoproterenol, cardiomyopathy, ARBs, MMP-9, cTn-i, candesartan, irbesartan

Abstract

The presence of a wide selection of angiotensin receptor blockers and the conflicting evidence regarding their cardioprotective effect, led to the attempt to evaluate the impact of irbesartan and candesartan on cardiac hypertrophy and remodeling. Female Albino rats were divided into 3 groups. The first group served as the control group and was given 1 ml distilled water via oral gavage and 0.5 ml distilled water subcutaneously. The second group was the isoproterenol (ISO) group and was given a daily S.C. injection of ISO at a dose of 5 mg/kg. The third group served as the treatment group and it was subdivided into 2 groups, both received ISO as stated previously along with a treatment drug which was administered via oral gavage and they included: ISO-Irb(irbesartan 50 mg/kg/day), and ISO-Cand(candesartan 2.6 mg/kg/day). All groups were treated for a period of 14 days. The assayed parameters included; mean serum Matrix metalloproteinase 9 (MMP-9), Cardiac troponin I (cTn-I), and Heart weight to Body weight (Hw/Bw) ratio.

Downloads

How to Cite

The Cardioprotective Effects of Irbesartan and Candesartan in Isoproterenol Induced Cardiomyopathy in Rats. (2014). Global Journal of Medical Research, 14(B6), 17-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/737

Download Citation

References

L Babuin, A Jaffe (2005) Troponin: the Biomarker of choice for the detection of Cardiac Injury. 173(10), 1191-1202.

M Boluyt, X Long, T Eschenhagen, U Mende, W Schmitz, M Crow, E Lakatta (1995) Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. 269(2), H638-H647.

S Brady, M York, C Scudamore, T Williams, W Griffiths, J Turton (2010) Cardiac troponin I in isoproterenol-induced cardiac injury in the Hanover Wistar rat: studies on low dose levels and routes of administration. 38(2), 287-291.

A Burke (2011) Unknown Title.

Michel Burnier (2001) Angiotensin II Type 1 Receptor Blockers. 103(6), 904-912.

Yu-Si Cheng, De-Zai Dai, Yin Dai (2009) Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCε in the heart, which are mitigated by endothelin receptor antagonist CPU0213. 30(8), 1099-1106.

D Chowdhury, A Tangutur, T Khatua, P Saxena, S Banerjee, M Bhadra (2013) A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats. 11(1), 1-13.

A Deschamps, F Spinale (2006) Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation. 69(3), 666-676.

Delisa Fairweather, Eric D., Michael J. (2011) Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. 16, 323-348.

Sam Gopald (2013) New and emerging biomarkers in left ventricular systolic dysfunction-insight into dilated cardiomyopathy. 6, 516-527.

M Gray, C Long, J Kalinyak, H Li, J Karliner (1998) Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblasts. 40(2), 352-363.

D Grimm, D Elsner, H Schunkert, M Pfeifer, D Griese, G Bruckschlegel, F Muders, G Riegger, E Kromer (1998) Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. 37(1), 91-100.

Pamela Harvey, Leslie Leinwand (2011) Cellular mechanisms of cardiomyopathy. 194(3), 355-365.

L Heather, M Cole, C Lygate, R Evans, D Stuckey, A Murray, S Neubauer, K Clarke (2009) Fatty acid transporter levels and palmitate oxidation rate correlate with ejection fraction in the infarcted rat heart. 72(3), 430-437.

Eugene Herman, Jun Zhang, Steven Lipshultz, Nader Rifai, Douglas Chadwick, Kazuyo Takeda, Zu-Xi Yu, Victor Ferrans (1999) Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin. 17(7), 2237-2237.

S Ichihara, T Senbonmatsu, E Price, T Ichiki, F Gaffney, T Inagami (2001) Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. 104(3), 346-351.

Shokei Kim, Hiroshi Iwao (2000) Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases. 52(1), 11-34.

H Kakuta, K Sudoh, M, Yamagishi (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. 25(1), 41-46.

Lili Li, Yao Zhang, Yongli Li, Bo Yu, Yan Xu, Shidan Zhao, Zhenzhong Guan (2008) Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. 21(12), 1181-1189.

Barry Maron, Jeffrey Towbin, Gaetano Thiene, Charles Antzelevitch, Domenico Corrado, Donna Arnett, Arthur Moss, Christine Seidman, James Young (2006) Contemporary Definitions and Classification of the Cardiomyopathies. 113(14), 1807-1816.

Charles Mccartan, Robert Mason, S Jayasinghe, Lyn Griffiths (2012) Cardiomyopathy Classification: Ongoing Debate in the Genomics Era. 2012, 1-10.

P Mehta, K Griendling (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 292(1), C82-C97.

G Montalescot, H Drexler, R Gallo, T Pearson, M Thoenes, D Bhatt (2009) Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. 30(22), 2733-2741.

María Ocaranza, Guillermo Díaz-Araya, Mario Chiong, David Muñoz, Juan Riveros, Roberto Ebensperger, Sebastián Sabat, Pablo Irarrázaval, Jorge Jalil, Sergio Lavandero (2002) Isoproterenol and Angiotensin I-Converting Enzyme in Lung, Left Ventricle, and Plasma During Myocardial Hypertrophy and Fibrosis. 40(2), 246-254.

A Palaniyappan, R Uwiera, H Idikio, B Jugdutt (2009) Comparison of Vasopeptidase inhibitor Omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. 321(1-2), 9-22.

C Richer, P Fornes, C Cazaubon, V Domergue, D Nisato, J Giudicelli (1999) Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. 41(1), 100-108.

Vanessa Roldán, Francisco Marín, Juan Gimeno, Francisco Ruiz-Espejo, Josefa González, Eloisa Feliu, Antonio García-Honrubia, Daniel Saura, Gonzalo De La Morena, Mariano Valdés, Vicente Vicente (2008) Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. 156(1), 85-91.

Andrey Serra, Maria Higuchi, Silvia Ihara, Ednei Antônio, Marília Santos, Maria Bombig, Paulo Tucci (2008) Exercise Training Prevents β-Adrenergic Hyperactivity-Induced Myocardial Hypertrophy and Lesions. 10(6), 534-539.

K Shirai, K Watanabe, M Ma, M Wahed, M Inoue, Y Saito, P Suresh, T Kashimura, H Tachikawa, M Kodama, Y Aizawa (2005) Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. 269(1-2), 137-142.

Ulka Tipnis, Gui He, Suzhen Li, Gerald Campbell, Paul Boor (2000) Attenuation of Isoproterenol-mediated Myocardial Injury in Rat by an Inhibitor of Polyamine Synthesis. 9(5), 273-280.

Paolo Verdecchia, Fabio Angeli, Salvatore Repaci (2009) Comparative assessment of angiotensin receptor blockers in different clinical settings. (5), 939-948.

Randy Wexler, Terry Elton, Christopher Taylor, Adam Pleister, David Feldman (2009) Physician reported perception in the treatment of high blood pressure does not correspond to practice. 10(1), 778-784.

Malcolm York, Cheryl Scudamore, Sally Brady, Christabelle Chen, Sharon Wilson, Mark Curtis, Gareth Evans, William Griffiths, Matthew Whayman, Thomas Williams, John Turton (2007) Characterization of Troponin Responses in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat. 35(4), 606-617.